#ASH24: Hodgkin lymphoma

To update you on the exciting content presented at the 66th American Society of Hematology (ASH) Meeting and Exposition, Dec 7–10, 2024, San Diego, US, we have collated our social media coverage. Catch up with our live social media relating to Hodgkin lymphoma, here.

CONGRESS | #ASH24 | POSTER
Bruce D. Cheson, Center for Cancer and Blood Disorders, shared long term data from a phase II trial of brentuximab vedotin and nivolumab in older (>60 yrs) patients with untreated Hodgkin #lymphoma.
At a median follow-up of 58.5 months, 58.7% of the… pic.twitter.com/Q3NtQOlvgV

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | Alison Moskowitz @MSKCancerCenter discusses the feasibility of pembrolizumab maintenance after pembro-GVD for R/R HL in CR. Overall 24-mo PFS 60%, stage I-III 24-mo PFS 72%, stage IV 24-mo PFS 37%. Pts with stage IV are more likely to require transplant.… pic.twitter.com/T6yWi2VyyQ

— Lymphoma Hub (@lymphomahub) December 9, 2024

CONGRESS | #ASH24 | Justin Ferdinandus @jusferdinandus @UKKoeln shares results from the phase II portion of the GHSG HD21 trial of PET-guided BrECADD in older patients with advanced-stage cHL. At a median FU of 23 mo, 12 mo PFS 95.1%, 24 mo PFS 91.5, 12 mo OS 96.2%, 24 mo OS… pic.twitter.com/u3sN9YgHzg

— Lymphoma Hub (@lymphomahub) December 9, 2024

CONGRESS | #ASH24 | PRESENTATION@LisaRoth_MD @WeillCornell shares updated results from the phase II KEYNOTE-667 trial.
After additional follow-up, pembrolizumab plus AVD consolidation, radiotherapy, and pembrolizumab maintenance demonstrated promising activity and a manageable… pic.twitter.com/lX0MUjRERb

— Lymphoma Hub (@lymphomahub) December 9, 2024